{
    "nct_id": "NCT05441501",
    "official_title": "A Phase 1 Study of JNJ-80038114, a T-Cell Redirecting Agent Targeting Prostate Specific Membrane Antigen (PSMA), for Advanced Stage Prostate Cancer",
    "inclusion_criteria": "* Metastatic castration-resistant prostate cancer (mCRPC) with confirmed adenocarcinoma of the prostate as defined by Prostate Cancer Working Group 3 (PCWG3)\n* Measurable or evaluable disease\n* At least 1 prior treatment for mCRPC\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Adequate organ functions as defined by certain laboratory values\n* Must sign an informed consent form (ICF)\n* Participants must agree to use a highly effective form of birth control as guided by the study doctor\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Concurrent anticancer therapy\n* Severe or long-lasting side effects related to prior anticancer therapy\n* Known allergies to JNJ-80038114 or its excipients\n* Brain metastasis or known seizure history\n* Significant infections or lung, heart or other medical conditions",
    "miscellaneous_criteria": ""
}